Bayer AG PK Valuation
| BAYRYDelisted Stock | USD 16.86 0.86 5.37% |
At this time, the firm appears to be overvalued. Bayer AG PK shows a prevailing Real Value of $13.47 per share. The current price of the firm is $16.86. Our model approximates the value of Bayer AG PK from analyzing the firm fundamentals such as Current Valuation of 87.41 B, profit margin of 0.09 %, and Return On Equity of 0.13 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Bayer AG's price fluctuation is very steady at this time. Calculation of the real value of Bayer AG PK is based on 3 months time horizon. Increasing Bayer AG's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Bayer AG PK is useful when determining the fair value of the Bayer pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Bayer AG. Since Bayer AG is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bayer Pink Sheet. However, Bayer AG's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.86 | Real 13.47 | Hype 16.86 | Naive 16.39 |
The real value of Bayer Pink Sheet, also known as its intrinsic value, is the underlying worth of Bayer AG PK Company, which is reflected in its stock price. It is based on Bayer AG's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Bayer AG's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bayer AG's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bayer AG PK helps investors to forecast how Bayer pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bayer AG more accurately as focusing exclusively on Bayer AG's fundamentals will not take into account other important factors: Bayer AG Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Bayer AG's current stock value. Our valuation model uses many indicators to compare Bayer AG value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bayer AG competition to find correlations between indicators driving Bayer AG's intrinsic value. More Info.Bayer AG PK is rated below average in price to earning category among related companies. It is rated below average in price to book category among related companies fabricating about 0.11 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Bayer AG PK is roughly 9.17 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bayer AG by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bayer AG's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bayer AG's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Bayer AG's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Bayer AG and how it compares across the competition.
About Bayer AG Valuation
The pink sheet valuation mechanism determines the current worth of Bayer AG PK on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Bayer AG PK. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bayer AG PK based exclusively on its fundamental and basic technical indicators. By analyzing Bayer AG's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Bayer AG's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bayer AG. We calculate exposure to Bayer AG's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Bayer AG's related companies.Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Aktienges is traded on OTC Exchange in the United States.
8 Steps to conduct Bayer AG's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bayer AG's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bayer AG's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bayer AG's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bayer AG's revenue streams: Identify Bayer AG's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bayer AG's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bayer AG's growth potential: Evaluate Bayer AG's management, business model, and growth potential.
- Determine Bayer AG's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bayer AG's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
A single share of Bayer AG represents a small ownership stake in the entity. As a stockholder of Bayer, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Bayer AG Dividends Analysis For Valuation
Please note that Bayer AG has scaled down on payment of dividends at this time.
There are various types of dividends Bayer AG can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Bayer shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Bayer AG PK directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Bayer pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Bayer AG by the value of the dividends paid out.
Bayer AG Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Bayer AG does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 982.4 M | |
| Quarterly Earnings Growth Y O Y | 5.424 | |
| Forward Price Earnings | 6.5833 | |
| Retained Earnings | 13.3 B |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Bayer Pink Sheet
If you are still planning to invest in Bayer AG PK check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bayer AG's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stocks Directory Find actively traded stocks across global markets |